Medivir’s Annual Report for 2017 is published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2017 now is available at the company’s website:

In 2017, Medivir could present groundbreaking results from the company's first phase IIa study with MIV-711 for the treatment of osteoarthritis. In oncology, Medivir's focus area, strong phase II data were presented for remetinostat against Cutaneous T-cell Lymphoma. Furthermore, during the year a phase I/II study with birinapant was initiated in combination with Merck's Keytruda® for the treatment of advanced solid tumors. The preclinical projects developed well during the year. This and much more can be found in Medivir's Annual Report for 2017, published today at

For further information, please contact:
Erik Björk, CFO Medivir AB, phone: +46 (0)72 228 2831


About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).


About Us

Medivir develops innovative pharmaceuticals for the treatment of cancer. The company specializes within protease inhibitor research and nucleotide/nucleoside science.The research is conducted in all phases of pharmaceutical development, from idea to clinical phase III studies. The development work is conducted both in-house and through partnerships.Medivir is listed on the Nasdaq Stockholm Mid Cap List.